Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Background: Previously considered inoperable patients (borderline resectable, locally
advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma …

Objective: This nationwide multicenter study aimed to define clinically relevant thresholds of
relative serum CA19-9 response after 2 months of induction chemotherapy in patients with …

Objective: To investigate whether revision of pancreatic neck margin based on
intraoperative frozen section analysis has oncologic value in post-neoadjuvant …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …

Objective: In this prospective study, we aim to characterize the prognostic value of circulating
tumor DNA (ctDNA) by next-generation-sequencing (NGS) in patients undergoing …

Background Changes in tumor size and serum carbohydrate antigen 19-9 are commonly
reported markers used to assess response to neoadjuvant therapy in pancreatic ductal …

Abstract Background/Purpose This study reports the long‐term results of a phase II trial
evaluating the clinical efficacy of neoadjuvant gemcitabine, nab‐paclitaxel, and S1 (GAS) in …

Background Matrix metalloproteinase 11 (MMP11) plays a vital role in cell proliferation,
apoptosis, tumor angiogenesis, migration, and other basic processes. Currently, few studies …

Objective: To investigate in patients treated for a resectable pancreatic ductal
adenocarcinoma [pancreatic adenocarcinoma (PA)], the prognostic value of baseline …